Does the media favor GMAB or AMRX?

In the previous week, Genmab A/S had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 10 mentions for Genmab A/S and 7 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.12 beat Genmab A/S's score of 0.19 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMRX or ASND?

In the previous week, Amneal Pharmaceuticals had 1 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 6 mentions for Ascendis Pharma A/S. Amneal Pharmaceuticals' average media sentiment score of 1.12 beat Ascendis Pharma A/S's score of 0.64 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMRX or BBIO?

In the previous week, BridgeBio Pharma had 12 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 19 mentions for BridgeBio Pharma and 7 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.12 beat BridgeBio Pharma's score of 0.72 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMRX or ELAN?

In the previous week, Elanco Animal Health had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 8 mentions for Elanco Animal Health and 7 mentions for Amneal Pharmaceuticals. Elanco Animal Health's average media sentiment score of 1.37 beat Amneal Pharmaceuticals' score of 1.12 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Amneal Pharmaceuticals (AMRX) Competitors

$17.50 -0.35 (-1.96%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$17.48 -0.02 (-0.14%)

As of 07/20/2026 07:56 PM Eastern

Compare

AMRX vs. VTRS, GMAB, ASND, BBIO, and ELAN

Should you buy Amneal Pharmaceuticals stock or one of its competitors? MarketBeat compares Amneal Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amneal Pharmaceuticals include Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Amneal Pharmaceuticals compare to Viatris?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Amneal Pharmaceuticals has a net margin of 4.01% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Viatris	-2.04%	19.04%	7.62%

Amneal Pharmaceuticals currently has a consensus price target of $16.60, suggesting a potential downside of 5.14%. Viatris has a consensus price target of $17.50, suggesting a potential upside of 3.00%. Given Viatris' higher probable upside, analysts plainly believe Viatris is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Amneal Pharmaceuticals had 7 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 0 mentions for Viatris. Amneal Pharmaceuticals' average media sentiment score of 1.12 beat Viatris' score of 0.00 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Amneal Pharmaceuticals	Positive
Viatris	Neutral

Amneal Pharmaceuticals has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.85	$72.06M	$0.38	46.05
Viatris	$14.30B	1.38	-$3.51B	-$0.26	N/A

Amneal Pharmaceuticals has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Viatris has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Amneal Pharmaceuticals beats Viatris on 11 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Genmab A/S had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 10 mentions for Genmab A/S and 7 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.12 beat Genmab A/S's score of 0.19 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has higher revenue and earnings than Amneal Pharmaceuticals. Genmab A/S is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.68	$963M	$1.32	21.14
Amneal Pharmaceuticals	$3.02B	1.85	$72.06M	$0.38	46.05

Genmab A/S presently has a consensus target price of $38.21, indicating a potential upside of 36.92%. Amneal Pharmaceuticals has a consensus target price of $16.60, indicating a potential downside of 5.14%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts clearly believe Genmab A/S is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Genmab A/S has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Genmab A/S has a net margin of 21.05% compared to Amneal Pharmaceuticals' net margin of 4.01%. Genmab A/S's return on equity of 15.34% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%

Summary

Genmab A/S beats Amneal Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Ascendis Pharma A/S?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals presently has a consensus price target of $16.60, suggesting a potential downside of 5.14%. Ascendis Pharma A/S has a consensus price target of $295.67, suggesting a potential upside of 17.44%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

Amneal Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.85	$72.06M	$0.38	46.05
Ascendis Pharma A/S	$865.78M	18.14	-$258M	$8.67	29.04

In the previous week, Amneal Pharmaceuticals had 1 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 6 mentions for Ascendis Pharma A/S. Amneal Pharmaceuticals' average media sentiment score of 1.12 beat Ascendis Pharma A/S's score of 0.64 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to Amneal Pharmaceuticals' net margin of 4.01%. Ascendis Pharma A/S's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Amneal Pharmaceuticals has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Amneal Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to BridgeBio Pharma?

Amneal Pharmaceuticals (NASDAQ:AMRX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

In the previous week, BridgeBio Pharma had 12 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 19 mentions for BridgeBio Pharma and 7 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.12 beat BridgeBio Pharma's score of 0.72 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.85	$72.06M	$0.38	46.05
BridgeBio Pharma	$502.08M	31.50	-$724.93M	-$3.74	N/A

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Amneal Pharmaceuticals presently has a consensus target price of $16.60, suggesting a potential downside of 5.14%. BridgeBio Pharma has a consensus target price of $95.21, suggesting a potential upside of 17.89%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Amneal Pharmaceuticals has a net margin of 4.01% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Summary

Amneal Pharmaceuticals beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Amneal Pharmaceuticals presently has a consensus target price of $16.60, indicating a potential downside of 5.14%. Elanco Animal Health has a consensus target price of $28.55, indicating a potential upside of 13.39%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts plainly believe Elanco Animal Health is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Amneal Pharmaceuticals has a net margin of 4.01% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Elanco Animal Health	-4.95%	7.42%	3.66%

Amneal Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.85	$72.06M	$0.38	46.05
Elanco Animal Health	$4.72B	2.67	-$232M	-$0.50	N/A

Amneal Pharmaceuticals has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Elanco Animal Health had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 8 mentions for Elanco Animal Health and 7 mentions for Amneal Pharmaceuticals. Elanco Animal Health's average media sentiment score of 1.37 beat Amneal Pharmaceuticals' score of 1.12 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elanco Animal Health beats Amneal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Amneal Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMRX vs. The Competition

Export

Metric	Amneal Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.69B	$3.07B	$6.89B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	46.05	20.20	27.06	23.94
Price / Sales	1.85	340.68	514.89	90.87
Price / Cash	11.43	27.11	26.68	47.25
Price / Book	-76.09	4.20	10.66	6.14
Net Income	$72.06M	$65.94M	$3.60B	$331.74M
7 Day Performance	4.85%	-3.05%	-1.23%	-1.81%
1 Month Performance	7.96%	-1.30%	1.11%	-1.44%
1 Year Performance	121.24%	15.22%	23.65%	16.33%

Amneal Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMRX Amneal Pharmaceuticals	2.5402 of 5 stars	$17.50 -2.0%	$16.60 -5.1%	+119.6%	$5.69B	$3.02B	46.05	8,500	News Coverage Positive News
VTRS Viatris	1.8785 of 5 stars	$16.40 +0.0%	$17.50 +6.7%	+91.3%	$19.09B	$14.30B	N/A	30,000	Positive News
GMAB Genmab A/S	4.5289 of 5 stars	$29.02 +0.7%	$38.21 +31.7%	+27.6%	$18.09B	$3.72B	21.98	3,029	Positive News
ASND Ascendis Pharma A/S	4.4398 of 5 stars	$267.23 +0.8%	$295.67 +10.6%	+48.2%	$16.68B	$814.57M	30.84	1,189	Positive News Analyst Downgrade
BBIO BridgeBio Pharma	3.5907 of 5 stars	$83.96 +1.1%	$94.63 +12.7%	+73.6%	$16.46B	$502.08M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMRX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. VTRS, GMAB, ASND, BBIO, and ELAN

How does Amneal Pharmaceuticals compare to Viatris?

Summary

How does Amneal Pharmaceuticals compare to Genmab A/S?

Summary

How does Amneal Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Amneal Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. VTRS, GMAB, ASND, BBIO, and ELAN

How does Amneal Pharmaceuticals compare to Viatris?

Is AMRX or VTRS more profitable?

Do analysts prefer AMRX or VTRS?

Does the media refer more to AMRX or VTRS?

Which has stronger valuation and earnings, AMRX or VTRS?

Which has more volatility and risk, AMRX or VTRS?

Do institutionals and insiders hold more shares of AMRX or VTRS?

Summary

How does Amneal Pharmaceuticals compare to Genmab A/S?

Does the media favor GMAB or AMRX?

Which has higher earnings and valuation, GMAB or AMRX?

Do analysts rate GMAB or AMRX?

Do insiders and institutionals have more ownership in GMAB or AMRX?

Which has more volatility & risk, GMAB or AMRX?

Is GMAB or AMRX more profitable?

Summary

How does Amneal Pharmaceuticals compare to Ascendis Pharma A/S?

Do insiders and institutionals hold more shares of AMRX or ASND?

Do analysts rate AMRX or ASND?

Which has higher valuation and earnings, AMRX or ASND?

Does the media prefer AMRX or ASND?

Is AMRX or ASND more profitable?

Which has more risk and volatility, AMRX or ASND?

Summary

How does Amneal Pharmaceuticals compare to BridgeBio Pharma?

Does the media favor AMRX or BBIO?

Which has more volatility and risk, AMRX or BBIO?

Which has preferable valuation & earnings, AMRX or BBIO?

Do institutionals and insiders hold more shares of AMRX or BBIO?

Do analysts recommend AMRX or BBIO?

Is AMRX or BBIO more profitable?

Summary

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Do analysts recommend AMRX or ELAN?

Is AMRX or ELAN more profitable?

Which has preferable valuation and earnings, AMRX or ELAN?

Which has more volatility and risk, AMRX or ELAN?

Do insiders & institutionals believe in AMRX or ELAN?

Does the media favor AMRX or ELAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools